Close Menu

Merrimack Pharmaceuticals CEO Robert Mulroy says the traditional approach to cancer — making drugs that go after certain proteins — is "fundamentally flawed," according to the Forbes' Treatments blog's Robert Langreth. Merrimack is now working with Sanofi-Aventis to develop cancer drugs using the principles of systems biology.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.